Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration

Australia's TGA has approved NIKTIMVO for chronic graft-versus-host disease after two prior therapies fail. Here's what the 74% response rate means for patients.

Reported Monday, Nov 3 - 9:23am EST (TheFly subscription required to read more.)

The Therapeutic Goods Administration in Australia has granted approval to NIKTIMVO (axatilimab) for chronic graft-versus-host disease. This first-in-class therapy marks a significant advancement in treatment options.

Niktimvo's FDA approval marks a major advance in chronic GVHD treatment, targeting inflammation and fibrosis with proven efficacy across various patient groups.

Syndax reveals its significant accomplishments in 2024 at the J.P. Morgan Healthcare Conference, focusing on groundbreaking therapies and future milestones.

Syndax Pharmaceuticals will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, showcasing its innovative cancer therapies and company achievements.

Syndax Pharmaceuticals has announced the granting of inducement awards for new employees under NASDAQ rules, signaling growth in cancer therapy development.

Syndax Pharmaceuticals has reported inducement grants under NASDAQ Rule 5635(c)(4), awarding stock options to new hires, reinforcing its commitment to innovation.

NIKTIMVO ® approved by the Therapeutic Goods Administration under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval by the US FDA Australian-led research played key role in the development of...